Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294507385> ?p ?o ?g. }
- W4294507385 abstract "ABSTRACT Immune checkpoint blockade (ICB) therapy has improved long-term survival for patients with advanced melanoma. However, there is critical need to identify potential biomarkers of response and actionable strategies to improve response rates. Through generation and analysis of 148 chromatin modification maps for 36 melanoma samples from patients treated with anti-PD- 1, we identified significant enrichment of active enhancer states in non-responders at baseline. Analysis of an independent cohort of 20 samples identified a set of 437 enhancers that predicted response to anti-PD-1 therapy (Area Under the Curve of 0.8417). The activated non-responder enhancers marked a group of key regulators of several pathways in melanoma cells (including c- MET, TGFβ, EMT and AKT) that are known to mediate resistance to ICB therapy and several checkpoint receptors in T cells. Epigenetic editing experiments implicated involvement of c-MET enhancers in the modulation of immune response. Finally, inhibition of enhancers and repression of these pathways using bromodomain inhibitors along with anti-PD-1 therapy significantly decreased melanoma tumor burden and increased T-cell infiltration. Together, these findings identify a potential enhancer-based biomarker of resistance to anti-PD-1 and suggest enhancer blockade in combination with ICB as a potential strategy to improve responses." @default.
- W4294507385 created "2022-09-03" @default.
- W4294507385 creator A5002293304 @default.
- W4294507385 creator A5006730640 @default.
- W4294507385 creator A5009222009 @default.
- W4294507385 creator A5015735715 @default.
- W4294507385 creator A5015813083 @default.
- W4294507385 creator A5017065981 @default.
- W4294507385 creator A5022037772 @default.
- W4294507385 creator A5026357113 @default.
- W4294507385 creator A5026383894 @default.
- W4294507385 creator A5027254356 @default.
- W4294507385 creator A5030829475 @default.
- W4294507385 creator A5032156128 @default.
- W4294507385 creator A5033798832 @default.
- W4294507385 creator A5035427219 @default.
- W4294507385 creator A5035641502 @default.
- W4294507385 creator A5036227254 @default.
- W4294507385 creator A5039476214 @default.
- W4294507385 creator A5047956338 @default.
- W4294507385 creator A5048327749 @default.
- W4294507385 creator A5051328429 @default.
- W4294507385 creator A5052198607 @default.
- W4294507385 creator A5054029425 @default.
- W4294507385 creator A5056079494 @default.
- W4294507385 creator A5058188181 @default.
- W4294507385 creator A5065355935 @default.
- W4294507385 creator A5068525042 @default.
- W4294507385 creator A5071539106 @default.
- W4294507385 creator A5074329224 @default.
- W4294507385 creator A5079886174 @default.
- W4294507385 creator A5079909397 @default.
- W4294507385 creator A5081518808 @default.
- W4294507385 creator A5081648218 @default.
- W4294507385 creator A5088432600 @default.
- W4294507385 creator A5089491252 @default.
- W4294507385 creator A5089977648 @default.
- W4294507385 date "2022-09-03" @default.
- W4294507385 modified "2023-09-29" @default.
- W4294507385 title "Enhancer Reprogramming in Melanoma Immune Checkpoint Therapy Resistance" @default.
- W4294507385 cites W1910012553 @default.
- W4294507385 cites W1970195561 @default.
- W4294507385 cites W2014677321 @default.
- W4294507385 cites W2015416439 @default.
- W4294507385 cites W2016326408 @default.
- W4294507385 cites W2018363492 @default.
- W4294507385 cites W2021341670 @default.
- W4294507385 cites W2035618305 @default.
- W4294507385 cites W2038555195 @default.
- W4294507385 cites W2060484997 @default.
- W4294507385 cites W2084160423 @default.
- W4294507385 cites W2095224412 @default.
- W4294507385 cites W2097995306 @default.
- W4294507385 cites W2101653483 @default.
- W4294507385 cites W2103021272 @default.
- W4294507385 cites W2107484016 @default.
- W4294507385 cites W2107922733 @default.
- W4294507385 cites W2108855090 @default.
- W4294507385 cites W2110417468 @default.
- W4294507385 cites W2118705059 @default.
- W4294507385 cites W2122730216 @default.
- W4294507385 cites W2124985265 @default.
- W4294507385 cites W2128758225 @default.
- W4294507385 cites W2130410032 @default.
- W4294507385 cites W2137465688 @default.
- W4294507385 cites W2138207763 @default.
- W4294507385 cites W2146512944 @default.
- W4294507385 cites W2153162429 @default.
- W4294507385 cites W2160834915 @default.
- W4294507385 cites W2162557359 @default.
- W4294507385 cites W2169353806 @default.
- W4294507385 cites W2169456326 @default.
- W4294507385 cites W2171613528 @default.
- W4294507385 cites W2171808845 @default.
- W4294507385 cites W2179438025 @default.
- W4294507385 cites W2180863202 @default.
- W4294507385 cites W2185693210 @default.
- W4294507385 cites W2201379305 @default.
- W4294507385 cites W2213269341 @default.
- W4294507385 cites W2259938310 @default.
- W4294507385 cites W2291659253 @default.
- W4294507385 cites W2295526061 @default.
- W4294507385 cites W2332292689 @default.
- W4294507385 cites W2341539131 @default.
- W4294507385 cites W2406250479 @default.
- W4294507385 cites W2481104931 @default.
- W4294507385 cites W2520148131 @default.
- W4294507385 cites W2522313999 @default.
- W4294507385 cites W2523285811 @default.
- W4294507385 cites W2578657671 @default.
- W4294507385 cites W2604130415 @default.
- W4294507385 cites W2619094261 @default.
- W4294507385 cites W2638401050 @default.
- W4294507385 cites W2736730167 @default.
- W4294507385 cites W2743925332 @default.
- W4294507385 cites W2747774814 @default.
- W4294507385 cites W2752211734 @default.
- W4294507385 cites W2785803176 @default.
- W4294507385 cites W2789833802 @default.
- W4294507385 cites W2791328450 @default.